Printer Friendly

Comparison of two methods forecasting binding rate of plasma protein.

1. Introduction

Pharmacokinetic (PK) often uses mathematical models and equations to study quantitative change law of medicines with time [1, 2]. PK is divided into several areas including the extent and rate of absorption, distribution, metabolism, and excretion [3]. It is mainly used to build mathematical expressions to monitor individual in vivo dose or drug regimen with time and work out PK parameters, make out, and adjust individual regimen to guarantee effectiveness and safety of treatment by applying PK model, expression, and parameters [4, 5]. After a drug is absorbed into vein, most of it is bound with plasma protein. Combining percentage of a drug for therapeutic dose and plasma protein is called binding rate of plasma protein (BRPP) [6]. In this paper, BRPP is stable because it is a measured value for normal people in normal dose. Free drug can diffuse to organisms by lipid membrane. And it can be filtered by tubules or metabolized by liver [7]. Consequently, combination of drug and protein can have evident effect on process of drug distribution and elimination and decrease drug potency at the target site. Some studies indicate that pharmacodynamic and pharmacokinetic is mainly influenced by its binding protein, so does bioavailability [7-10]. The higher BRPP is, the longer its half-life is. Among R&D projects, about percent forty candidate compounds fell into disuse because of poor PK parameters, such as slow absorbing speed, low bioavailability, high BRPP, quick metabolization leading to short duration of drug action, and metabolites with toxicity and slow excretion leading to accumulated toxicity, in a body [11]. These reasons make in vitro activity of the compounds to lose the developing values of clinical drugs [12]. Therefore, for feasible drug design, we must consider characteristics of pharmacodynamic and pharmacokinetic to achieve the best balance between them. It is an important content of drug design for quantitative structure pharmacokinetic relationship (QSPKR) [13, 14] and quantitative structure-activity relationship (QSAR) [15, 16]. At the same time, they are also successfully used to forecast characteristics of drugs such as drug metabolism, toxicity, and actual bioavailability. Computer-aided drug design (CADD) is becoming an important research field of new drug development [17], which can apply known knowledge of drug molecules and biological targets to find and design new kinds of drug molecules by theoretical simulation and calculation [18]. At present, it is a very active area to study PK models in pharmaceutical industry. Because drug BRPP is influenced by many factors, causality and mechanism are not clear and distinct between molecular structures of drugs. As far as the present scientific level is concerned, there are still many difficulties to clarify relations between them according to basic principles. Classical forecasting methods (e.g., multiple linear regression) face more and more dilemmas. However, artificial intelligence methods provide stronger tools to analyze existed PK data and construct QSPKR between BRPP and molecular structure variables of a drug. In particular, the results of practical application in other fields indicate that the performance of support vector machine (SVM) has superiority over ANN and can overcome the problems of overfitting and local minimization of traditional neural networks excellently.

In order to find a new method to construct a PK model of BRPP, we establish QSAR models by Heuristic algorithm (HA) and SVM with BRPP of seventy drugs and test forecasting performance and stability of a SVM model.

The remainder of the paper is organized as follows. Principles of research methods are introduced in Section 2. Empirical study is presented in Section 3. Finally, conclusive results are drawn in Section 4.

2. Data Resource and Methodology

2.1. Data Resource and Structure Parameters. All experimental data of seventy drugs and their BRPPs resource are from reference [19]. Models are constructed by training set consisting of fifty-six drugs chosen randomly. Data of the remaining fourteen drugs as test set are used to examine stability and forecast performance of the two models. All compounds are initially optimized by molecular mechanics method (MM+) in program Hyperchem 4.0. Then, they are geometrically optimized further by semiempirical method (AM1). Optimized molecular structure is calculated in MOPAC 6.0, and then the results are transferred into CODESSA program to calculate five kinds of descriptors (independent variables): composition descriptor, topological descriptor, geometric descriptor, electrostatic descriptor, and quantum chemical descriptor.

2.2. Heuristic Algorithm. HA can entirely search for a great quantity of molecular descriptors in software CODESSA and establish optimal linear regression equation [20]. HA has to control collinearity of molecular descriptors [21]. For example, if correlation coefficient of any two descriptors is more than 0.8, they will not be involved in the same model simultaneously. The optimal model is built by rapid filter and selection of HA to descriptors, while it is not done by considering all possible combination of descriptors. HA takes pretreatment way to eliminate some descriptors according to four rules: (1) the descriptors not owned by each compound; (2) descriptors with smaller changes of values for all compounds; (3) descriptors with F test value less than 1.0 in an equation; (4) descriptors with t test value less than a specific value [16]. Heuristic regression method (HRM) sequences molecular descriptors as descending order of correlation coefficients of a model. Every time, the descriptor with the biggest correlation coefficient is introduced among the remaining descriptors, which takes turn until the end. Performance of a model depends on multiple correlation coefficient ([R.sup.2]), F test value (F), standard deviation (s), and so forth [22]. Stability of a model is tested by correlation coefficient [R.sup.2.sub.cv] of cross-validation of leave-one-out (LOO) [23]. Briefly, eliminate a sample in data set and forecast the eliminated sample by building a new model with the same descriptors, take turns until every sample in data set is eliminated and forecasted once, and calculate correlation coefficient between a forecasted value and an observed value. Generally, speed and quality of HRM are higher than others, which makes it become the first choice in practice [24].

In this paper, errors of heuristic regression results are denoted by root mean square (RMS), and the equation is as follows:

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII], (1)

where [y.sub.k] is target value, [y.sub.k] is an observed value, [n.sub.c] is the quantity of compounds, and c denotes a compound.

2.3. Support Vector Machine. Principle of SVM is that maps input vector x into high-dimensional feature space by scheduled nonlinear mapping and then constructs optimal hyperplane in the high-dimensional space [25]. Thus, the problem is transformed into quadratic programming. No matter what target function or classification function it is, they both involve the inner product in quadratic programming. If a kernel function is used, it can avoid complex calculations in high-dimensional space and realize the inner calculations by an original space function. Consequently, selecting appropriate inner product K([x.sub.i], [y.sub.i]) can realize linear calculation of a nonlinear transformation, while it does not increase calculating complexity [26]. Support vector machine regression (SVRM) maps a variable x into high-dimensional feature space by a nonlinear constructor O, and the regression is done in the space 27].

Assume the given input sample x is a n-dimension vector, k samples and their output value y are denoted as follows:

([x.sub.1], [y.sub.1]), ..., ([x.sub.k], [y.sub.k]) [member of] [R.sup.n] x R. (2)

Regression analysis is also called function estimation, which is a statistical process for estimating the relationships among variables. For a given sample set {([x.sub.i], [y.sub.i]), i = 1, ..., k], where [x.sub.i] is the i independent factor (descriptor) and [y.sub.i] is the i dependent factor (BRPP). A regression model relates y to a function of x, y = f(x). If the function f(x) is linear, the regression is called as linear regression, otherwise called as nonlinear regression [28]. There is only one kind of sample points for SVMR, namely, optimal hyperplane which makes the total deviation minimized between all sample points and the hyperplane. Thus, sample points are between two borders. If insensitive function e is taken as an error function, the problem of how to find the optimal regression hyperplane is transformed to solve quadratic convex programming when the distances of all sample points to the quested hyperplane are not more than [epsilon] [25]. Namely,

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]. (3)

When distances of several sample points to the hyperplane are more than e, deviation of insensitive function [epsilon] is equivalently the introduced slack variable [[xi].sub.i] of SVM clustering. Introducing fault-tolerant penalty function C, the problem of quadratic convex programming to find the optimal regression hyperplane can be transformed as follows:

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]. (4)

Then, linear regression function of the optimal hyperplane is

f(x) = (w x x) + b = [summation over (S.V.)]([a.sub.i] - [a.sup.*.sub.i]) (x x [x.sub.i]) + b. (5)

[a.sub.i], [a.sup.*.sub.i], and b can be calculated through constraints; S.V. denotes support vector. In order to determine parameters of the optimal hyperplane, the above solving process can be realized by MATLAB program. Last results indicate that the optimal regression hyperplane is only determined by sample points. If points x and [x.sub.i] in sample space are replaced by mapped image point [psi](x) and [psi]([x.sub.i]) with a kernel function; let K(x, [x.sub.i]) = ([psi](x) x [psi]([x.sub.i])); L denotes number of points [29]; then,

f(x) = (w x [psi](x)) + b = [L.summation over (i=1)]([a.sub.i] - [a.sup.*.sub.i])K(x, [x.sub.i]) + b. (6)

3. Empirical Analysis

3.1. HA Model. Each molecule can be worked out to five hundred to six hundred descriptors by using CODESSA, including composition, topological, geometric, electrostatic, and quantum chemical descriptors. Composition descriptor reflects the composition information of a molecule, including quantity of atoms, atomic bonds, atomic rings, and molecular weight. Topological descriptor indicates connecting information of atoms in a molecule, including Wiener index, Randic index, and Kier-Hall index. Geometric descriptor reveals size and shape of a molecule, including inertia moment, molecular cubage, and surface area. Electrostatic descriptor displays distribution information of electric charges in a molecule, including maximum and minimum partial charges, polarity, and charged partial surface area (CPSA). Quantum chemical descriptor discloses electric charge distribution in a molecule and energy information of molecular orbit, including reaction index, dipole moment, energy of lowest unoccupied molecular orbital (LUMO), and highest occupied molecular orbital (HOMO), which has an important effect on molecular reaction, electrostatic interaction between molecules, and interaction between molecular orbits. By HM filtering, six parameters are introduced to the model. Their interrelations and forecasting results are seen in Tables 1 and 2. In HA model, correlation coefficient [R.sup.2] = 0.85, test value F = 63.64, error RMS = 12.24, and correlation coefficient of cross-validation [R.sup.2.sub.cv] = 0.80 (see Figure 1 and Table 3).

There are six descriptors in HA linear model. WPSA-3 weighted PPSA (Zefirov's PC), HASA-1/TMSA (Zefirov's PC), and PNSA-2 total charge weighted PNSA are electrostatic descriptors. ALFA polarizability (DIP), Tot pointcharge compd. of the molecular dipole and final heat of formation are quantum chemical descriptors. [alpha]-polarizability is molecular polarizability which reflects molecular cubage and interaction between agent and molecule. Polarizability scale is closely related to hydrophobicity and electrophilicity. In the model, only the signal of [alpha]-polarizability parameter is positive, which indicates that polarizability has a positive effect on bond of drug and plasma protein. Hydrophobicity influences combination of drug and plasma protein directly. Because protein consists of polypeptides with electric charge, the stronger electrophilicity is, the easier binding with plasma protein is. Final heat of formation (FHF) is relative to molecular stability, which expresses molecular reaction ability. Change of FHF influences molecular structure and function, while it does the combination of drug molecule and plasma protein. WPSA-3 weighted PPSA is partial positive surface charge. PNSA-2 total charge weighted PNSA is the weights of total charges and determined by surface area and functional gene of molecule, which reflects interactions between polarmolecules. On the surface of plasma protein, there are enzymes with specific function gene. At the same time, there also exist a series of receptors. As the ligand, drug is bound with receptors on the surface of plasma protein. Consequently, change of function gene on the surface of drug molecule can have a significant effect on BRPP. HASA-1/TMSA is a ratio of surface area of hydrogen bond receptor to total surface area of molecule, which is a weight area of surface charge of hydrogen bond donor atoms. According to the above explanation, dipole moment between molecules and the surface of hydrogen-bonding acceptor and molecular surface are both main influencing factors of bond of drug and plasma protein. Tot point-charge compd. of the molecular dipole is the contribution of point charge to molecular dipole moment.

3.2. SVM Model. In order to compare performance of SVM with that of HA model, we choose the same test set, training set, descriptors with HA model. In SVM model, it is very crucial to choose kernel function. There are four kinds of kernel functions including linear, polynomial, Gaussian, and sigmoid. When size and dimension of samples are small, the four kernel functions can show better performance. On the contrary, Gaussian kernel is a better choice [30], which is most commonly used in SVMR; namely,

F(u, v) = exp (-[[gamma].sup.*][[absolute value of u - v].sup.2]), (7)

where [gamma] is a constant, u and v are two independent variables. y controls generalization ability of SVM by adjusting the shape of Gaussian function. Because size and dimension of samples are big in our study, Gaussian kernel function is a preferred choice. The forecasting results are seen in Table 2. After adjusting [gamma], [epsilon], and C simultaneously, we can get three useful results.

Firstly, seeing Figure 2, the error is minimal when [gamma] is 0.035. Optimal value of [epsilon] depends on data type while it also considers support vectors. Because insensitive function [epsilon] can control border of all training set, it is very important for SVM to choose [epsilon]. Secondly, relation between [epsilon] and errors is seen in Figure 3. When [epsilon] = 0.173, the error is the least.

Thirdly, another important parameter C is used to measure the training error between maximal and minimal hyperplane. If C is too small and training is not enough, it is very difficult to arrive to the optimal. On the contrary, overfitting phenomenon will happen. Relation between C and errors is seen in Figure 4. When C is equal to 130, the error is the least.

According to the above training results, when the optimal parameters [gamma], [epsilon], and C are equal to 0.035, 0.173, and 130 respectively, forecasting ability of the model is the most robust and stable. In Figure 5, RMS is 11.40. For training and test set, [R.sup.2] is 0.97 and 0.92, respectively. Total [R.sup.2.sub.cv] is 0.83.

Comparing HA with SVM, it is found that their correlation coefficient square ([R.sup.2]) is 0.80 and 0.83, respectively, after cross-validation, RMS is 12.24 and 11.40, respectively. Higher [R.sup.2] value and lower RMS value indicate a better predictability of the dependent variable from the independent variables [31]. Therefore, a conclusion can be drawn that SVM model has better stability and more robust forecasting ability for BRPP than HA model, which is a good tool to construct PK a model.

4. Conclusion

In this paper, we construct HA and SVM model to forecast BRPP, respectively. By calculating descriptors of molecular structure, we found that it is satisfactory for forecasting results of nonlinear QSAR model based on SVM and linear QSAR model based on HA. By comparison of two methods, nonlinear model based on SVM is more stable and more robust to forecast BRPP than linear model based on HA. Therefore, SVM model is a more effective tool to study QSAR and BRPP of a drug.

However, because the comparison is primarily based on the analysis of one real dataset, our research has certain limitations. The conclusions need research supports of more datasets. SVM performance of predicting BRPP should be studied and discussed further by more datasets in the future.

http://dx.doi.org/10.1155/2014/957154

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] A. Valladares-Mendez, E. Hernandez-Nunez, R. Cedillo-Rivera et al., "Synthesis, in vitro and in vivo giardicidal activity, and pharmacokinetic profile of a new mtazoxamde analog," Medicinal Chemistry Research, vol. 23, pp. 3157-3164, 2014.

[2] S. T. Stern, P. Zou, S. Skoczen et al., "Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion," Journal of Controlled Release, vol. 172, no. 2, pp. 558-567, 2013.

[3] B. L. Mui, Y. K. Tam, M. Jayaraman et al., "Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles," Molecular Therapy-Nucleic Acids, vol. 2, article e139, 2013.

[4] E. C. Jeunesse, M. Schneider, and F. Woehrle, "Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog," BMC Veterinary Research, vol. 9, article 250, 2013.

[5] Z. Durakovic and D. Vitezic, "Pharmacodynamics and pharmacokinetics in the elderly," Periodicum Biologorum, vol. 115, pp. 517-520, 2013.

[6] Y. Liang, Y. Zhou, Y. Liu et al., "Study on the plasma protein binding rate of Schisandra lignans based on the LC-IT-TOF/MS technique with relative quantitative analysis," Chinese Journal of Natural Medicines, vol. 11, no. 4, pp. 442-448, 2013.

[7] R. Deshmukh, N. Wishart, J. Voss et al., "Pharmacokinetic and pharmacodynamic implications of disease-associated changes in plasma protein binding," Drug Metabolism Reviews, vol. 43, pp. 178-179, 2011.

[8] H. Matsushima, H. Kamimura, Y. Soeishi, T. Watanabe, S. Higuchi, and M. Tsunoo, "Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans," Drug Metabolism and Disposition, vol. 26, no. 3, pp. 240-245, 1998.

[9] H. J. G. D. van den Bongard, D. Pluim, R. C. A. M. van Waardenburg, M. Ravic, J. H. Beijnen, and J. H. M. Schellens, "In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood," Anti-Cancer Drugs, vol. 14, no. 6, pp. 405-410, 2003.

[10] J. G. Teeguarden, J. M. Waechter Jr., H. J. Clewell III, T. R. Covington, and H. A. Barton, "Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach," Toxicological Sciences, vol. 85, no. 2, pp. 823-838, 2005.

[11] Y. Hong, P. J. Shaw, B. N. Tattam et al., "Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases," European Journal of Clinical Pharmacology, vol. 63, no. 2, pp. 165-172, 2007.

[12] E. Ezan, "Pharmacokinetic studies of protein drugs: past, present and future," Advanced Drug Delivery Reviews, vol. 65, no. 8, pp. 1065-1073, 2013.

[13] C. Ng, Y. Xiao, W. Putnam, B. Lum, and A. Tropsha, "Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods," Journal of Pharmaceutical Sciences, vol. 93, no. 10, pp. 2535-2544, 2004.

[14] G. Gottipati and J. Venitz, "Quantitative structure-pharmacokinetic (PK) properties-relationships (QSPKR) for benzodiazepines (BZD)," Clinical Pharmacology & Therapeutics, vol. 91, pp. S70-S70, 2012.

[15] C. W. Yap, H. Li, Z. L. Ji, and Y. Z. Chen, "Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties," Mini-Reviews in Medicinal Chemistry, vol. 7, no. 11, pp. 1097-1107, 2007

[16] K. Liu, B. Xia, W. Ma, B. Zheng, X. Zhang, and B. Fan, "Quantitative structure-activity relationship modeling of triaminotriazine drugs based on heuristic method," QSAR and Combinatorial Science, vol. 27, no. 4, pp. 425-431, 2008.

[17] M. L. Xiang, Y. Cao, W. Fan, L. Chen, and Y. Mo, "Computer-aided drug design: lead discovery and optimization," Combinatorial Chemistry & High Throughput Screening, vol. 15, no. 4, pp. 328-337, 2012.

[18] A. Cern, Y. Barenholz, A. Tropsha, and A. Goldblum, "Computer-aided design of liposomal drugs: in silico prediction and experimental validation of drug candidates for liposomal remote loading," Journal of Controlled Release, vol. 173, pp. 125-131, 2014.

[19] A. G. Gilman, The Pharmacological Basis of Therapeutics, McGraw-Hill, Health Professions Division, New York, NY, USA, 9th edition, 1996.

[20] F. Luan, W. Ma, H. Zhang et al., "Prediction of pKa for neutral and basic drugs based on radial basis function neural networks and the heuristic method," Pharmaceutical Research, vol. 22, no. 9, pp. 1454-1460, 2005.

[21] L. Hodes, G. F. Hazard, R. I. Geran, and S. Richman, "A statistical-heuristic method for automated selection of drugs for screening," Journal of Medicinal Chemistry, vol. 20, no. 4, pp. 469-475, 1977

[22] J. L. Yang, "BinAligner: a heuristic method to align biological networks," BMC Bioinformatics, vol. 14, supplement 14, article S8, 2013.

[23] J. Kukal and T. V. Quang, "Estimating a GARCH-M model by a non-parametric heuristic method and its advantages," Politicka Ekonomie, vol. 62, pp. 100-116, 2014.

[24] J. Verstichel, P. De Causmaecker, F. C. R. Spieksma, and G. Vanden Berghe, "Exact and heuristic methods for placing ships in locks," European Journal of Operational Research, vol. 235, no. 2, pp. 387-398, 2014.

[25] H. Zhang, W. Li, Y. Xie, W. Wang, L. Li, and S. Yang, "Rapid and accurate assessment of seizure liability of drugs by using an optimal support vector machine method," Toxicology in Vitro, vol. 25, no. 8, pp. 1848-1854, 2011.

[26] K. Kawai, S. Fujishima, and Y. Takahashi, "Predictive activity profiling of drugs by topological-fragment-spectra-based support vector machines," Journal of Chemical Information and Modeling, vol. 48, no. 6, pp. 1152-1160, 2008.

[27] Q. Huang, Y. Zhuang, X. Qiao, and X. Xu, "Predicted model of aggregation of molecules in Chinese herbal drugs by support vector machines," Acta Physico--Chimica Sinica, vol. 23, no. 8, pp. 1141-1144, 2007.

[28] Z. Bikadi, I. Hazai, D. Malik et al., "Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein," PLoS ONE, vol. 6, no. 10, Article ID e25815, 2011.

[29] C. Ma, S. Yang, H. Zhang, M. Xiang, Q. Huang, and Y. Wei, "Prediction models of human plasma protein binding rate and oral bioavailability derived by using GA-CG-SVM method," Journal of Pharmaceutical and Biomedical Analysis, vol. 47, no. 4-5, pp. 677-682, 2008.

[30] M. A. Mohandes, T. O. Halawani, S. Rehman, and A. A. Hussain, "Support vector machines for wind speed prediction," Renewable Energy, vol. 29, no. 6, pp. 939-947, 2004.

[31] R. M. Dodhia, "Applied multiple regression/correlation analysis for the behavioral sciences," Journal of Educational and Behavioral Statistics, vol. 30, pp. 227-229, 2005.

Liu Hongjiu and Hu Yanrong

Changshu Institute of Technology, Changshu 215500, China

Correspondence should be addressed to Liu Hongjiu; lionlhj@163.com

Received 25 May 2014; Revised 18 July 2014; Accepted 18 July 2014; Published 4 August 2014

Academic Editor: Maria N. D. S. Cordeiro

TABLE 1: Correlation matrix of the six descriptors (a).

Descriptor      1        2        3        4         5         6

1             1.000    0.177    0.776    0.039    -0.190    -0.559
2                      1.000    0.266    0.269    -0.104    -0.255
3                               1.000    0.129    -0.541    -0.592
4                                        1.000    -0.192    -0.497
5                                                  1.000     0.325
6                                                            1.000

(a) 1: ALFA polarizability (DIP), 2: WPSA-3 weighted PPSA (Zefirov's
PC), 3: HASA-1-TMSA (Zefirov's PC), 4: Tot point-charge compd. of the
molecular dipole, 5: PNSA-2 total charge weighted PNSA, and 6: final
heat of formation.

TABLE 2: Experimental and calculated BRPP based on HA and SVM.

No.               Compd.            BRPP/(%)      HA     Residual

1 (a)           Acebutolol            26.0       35.9       9.9
2               Alprenolol            85.0       61.5      -23.5
3               Amantadine            67.0       58.6      -8.4
4               Amiodarone            100.0     110.9      10.9
5             Amitriptyline           94.8      100.1       5.3
6 (a)            Aspirin              49.0       56.1       7.1
7             Betamethasone           64.0       62.9      -1.1
8               Bumetanide            99.0       92.6      -6.4
9                Caffeine             36.0       28.0      -8.0
10              Cefalexin             14.0       41.6      27.6
11 (a)         Chloroquine            61.0       67.7       6.7
12            Chlorthalidone          75.0       76.8       1.8
13              Cimetidine            19.0       17.2      -1.8
14            Ciprofloxacin           40.0       40.6       0.6
15           Diphenhydramine          78.0       83.2       5.2
16 (a)          Furosemide            98.8       85.8      -13.0
17            Glibenclamide           99.0      114.0      15.0
18             Haloperidol            92.0       91.3      -0.7
19              Lidocaine             70.0       60.6      -9.4
20              Methadone             89.0       94.3       5.3
21 (a)         Methotrexate           34.0       47.3      13.3
22            Metoclopramide          40.0       37.4      -2.6
23            Metronidazole           10.0       16.1       6.1
24              Nifedipine            96.0       91.0      -5.0
25            Phenobarbital           51.0       60.4       9.4
26 (a)           Pindoioi             51.0       53.6       2.6
27              Prednisone            75.0       58.0      -17.0
28              Quinidine             87.0       93.8       6.8
29              Ranitidine            15.0       15.7       0.7
30             Sulfadiazine           54.0       65.6      11.6
31 (a)       Sulfamethoxazole         62.0       56.4      -5.6
32             Terbutaline            20.0       39.2      19.2
33               Timolol              60.0       44.6      -15.4
34             Triamterene            61.0       58.9      -2.1
35               Amikacin              4.0      -12.4      -16.4
36 (a)        Carbamazepine           74.0       72.2      -1.8
37            Carbenicillin           50.0       63.9      13.9
38             Cefamandole            74.0       78.7       4.7
39              Cefazolin             89.0       72.4      -16.6
40              Cefotaxime            36.0       37.1       1.1
41 (a)          Cefuroxime            33.0       52.6      19.6
42           Chloramphenicol          53.0       37.7      -15.3
43            Chlorothiazide          94.6       83.2      -11.4
44              Clonazepam            86.0       83.1      -2.9
45               Cocaine              91.0       82.2      -8.8
46 (a)           Dapsone              73.0       69.0      -4.0
47            Dexamethasone           68.0       78.9      10.9
48               Diazepam             98.7       88.7      -10.0
49           Ethinylestradiol         98.0       86.2      -11.8
50              Famotidine            17.0       16.2      -0.8
51 (a)           Fentanyl             84.0       85.8       1.8
52              Flecainide            61.0       80.6      19.6
53         Hydrochlorothiazide        58.0       57.6      -0.4
54              Imipramine            90.1       93.6       3.5
55              Isoniazid              0.0       17.4      17.4
56 (a)   Isosorbide-5-mononitrate      0.0       10.7      10.7
57             Ketoconazole           99.0       90.4      -8.6
58              Lovastatin            95.0      101.3       6.3
59              Mexiletine            63.0       66.3       3.3
60              Nitrazepam            87.0       97.1      10.1
61 (a)        Norethisterone          80.0       76.1      -3.9
62              Omeprazole            95.0       89.9      -5.1
63              Pethidine             58.0       72.0      14.0
64            Phenylbutazone          96.1      104.5       8.4
65             Propafenone            97.0       79.6      -17.4
66 (a)         Propranolol            87.0       83.4      -3.6
67            Pyrimethamine           87.0       69.2      -17.8
68              Thiopental            85.0       76.8      -8.2
69             Ticarcillin            65.0       50.7      -14.3
70               Warfarin             99.0       88.0      -11.0

No.       SVM     Residual

1 (a)     40.0      14.0
2         72.9      -12.1
3         61.9      -5.1
4        100.3       0.3
5         90.1      -4.7
6 (a)     45.0      -4.0
7         61.0      -3.0
8         94.0      -5.0
9         30.9      -5.1
10        41.0      27.0
11 (a)    75.6      14.6
12        80.0       5.0
13        19.4       0.4
14        43.4       3.4
15        83.9       5.9
16 (a)    95.5      -3.3
17        95.1      -3.9
18        95.7       3.7
19        75.1       5.1
20        94.0       5.0
21 (a)    53.4      19.4
22        44.3       4.3
23        15.0       5.0
24        96.6       0.6
25        46.2      -4.8
26 (a)    69.0      18.0
27        69.9      -5.1
28       100.0      13.0
29        15.6       0.6
30        59.1       5.1
31 (a)    48.1      -13.9
32        25.1       5.1
33        65.1       5.1
34        66.1       5.1
35        5.4        1.4
36 (a)    81.8       7.8
37        55.0       5.0
38        76.1       2.1
39        83.9      -5.1
40        33.6      -2.4
41 (a)    53.4      20.4
42        47.9      -5.1
43        89.5      -5.1
44        80.9      -5.1
45        85.9      -5.1
46 (a)    66.6      -6.4
47        73.1       5.1
48        93.6      -5.1
49        92.9      -5.1
50        11.9      -5.1
51 (a)    90.2       6.2
52        66.0       5.0
53        63.0       5.0
54        85.0      -5.1
55        5.1        5.1
56 (a)   -11.8      -11.8
57       104.1       5.1
58       100.0       5.0
59        68.1       5.1
60        94.6       7.6
61 (a)    88.3       8.3
62        92.6      -2.4
63        76.3      18.3
64       101.2       5.1
65        91.0      -6.0
66 (a)    90.3       3.3
67        79.8      -7.2
68        79.9      -5.1
69        59.9      -5.1
70        94.0      -5.0

(a) test set.

TABLE 3: Correlation coefficient of six-descriptor in HA model.

Descriptor                                Coefficient          t-test

ALFA polarizability (DIP)            0.653 [+ or -] 0.056      11.755
(a) WPSA-3 Weighted PPSA            -10.969 [+ or -] 0.860    -12.756
  (Zefirov's PC)
(a) HASA-1/TMSA (Zefirov's PC)      -73.908 [+ or -] 14.802    -4.993
Tot point-charge compd. of the       -7.799 [+ or -] 0.918     -8.495
  molecular dipole
(a) PNSA-2 Total charge weighted     -0.036 [+ or -] 0.005     -7.757
  PNSA
Final heat of formation              -0.059 [+ or -] 0.016     -3.596

[R.sup.2] = 0.85, F = 63.64,
RMS = 12.24,
[R.sub.cv.sup.2] = 0.80

(a) TMSA: total molecular surface area; PNSA: partial negative surface
area; PPSA: partial positive surface area.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Hongjiu, Liu; Yanrong, Hu
Publication:Computational and Mathematical Methods in Medicine
Article Type:Report
Geographic Code:9CHIN
Date:Jan 1, 2014
Words:5039
Previous Article:A note regarding problems with interaction and varying block sizes in a comparison of endotracheal tubes.
Next Article:BioTCM-SE: a semantic search engine for the information retrieval of modern biology and traditional Chinese medicine.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters